2,645
Views
4
CrossRef citations to date
0
Altmetric
Research Article

High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma

ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all

References

  • Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, et al. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol. 2010;89:1045–1052.
  • Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, et al. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: real-world data from a single center. World J Clin Oncol. 2021;12:800–807.
  • Appelbaum FR, Herzig GP, Ziegler JL, et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood. 1978;52:85–95.
  • Anderson CC, Goldstone AH, Souhami RL, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol. 1986;16:170–175.
  • Olivieri J, Mosna F, Pelosini M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: An observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transpl. 2018;24:1814–1822.
  • Joffe E, Rosenberg D, Rozovski U, et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma. Bone Marrow Transpl. 2021;53:29–33.
  • Marchesi F, Capria S, Pedata M, et al. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant. Leukemia Lymph. 2020;61:2238–2241.
  • Kim K, Kim W, Kim S, et al. Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma: a multicenter study from the consortium for improving survival of lymphoma. Transpl Int. 2020;33:1211–1219.
  • López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44:715–719.
  • Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, et al. Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience. Acta Haematol. 2003;110:179–183.
  • Karduss-Urueta A, Gale RP, Gutiérrez-Aguirre CH, et al. Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplant. 2018;53:457–460.
  • Sugimoto M, Ito S, Mashima K, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95(9):1513–1519.
  • Al Hashmi H, Kaloyannidis P, Kafnar S, et al. Single-agent high-dose melphalan as conditioning regimen in autologous hematopoietic stem cell transplantation for Hodgkin’s lymphoma: safety, and long-term efficacy. Biol Blood Marrow Transpl. 2018;24:S132–S1S3.
  • Ruiz-Argüelles GJ. Whither the bone marrow transplant? Hematology. 2010;15:1–3.
  • Pai AA, Devasia AJ, Panetta JC, et al. Pharmacokinetics and efficacy of generic melphalan is comparable to innovator formulation in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2020;20:130–135.
  • Ruiz-Argüelles GJ. Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. Lancet Haematol. 2020;7:e509–e10.
  • Gale RP, Ruiz-Argüelles GJ. The big freeze may be over: a contracting universe for cryopreservation? Bone Marrow Transpl. 2018;53:947–948.